Hologic (HOLX) Gets NVVP Approval for Cervista HPV HR Test
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Up)Join SI Premium – FREE
Hologic, Inc. (Nasdaq: HOLX), announced that the NVVP (Netherlands Society for Pathology) has approved the use of the Hologic Cervista HPV HR test for detecting human papillomavirus in the Dutch national cervical screening programme.
HPV is one of the most common sexually transmitted diseases (STD) and is recognized as the cause of most cervical cancers. To help prevent the onset of disease, the RIVM (National Institute for Public Health and the Environment in The Netherlands) suggests routine Pap testing and HPV HR triage for ASCUS/LSIL testing for women over the age of 30 to identify women most likely to develop cervical cancer.
HPV is one of the most common sexually transmitted diseases (STD) and is recognized as the cause of most cervical cancers. To help prevent the onset of disease, the RIVM (National Institute for Public Health and the Environment in The Netherlands) suggests routine Pap testing and HPV HR triage for ASCUS/LSIL testing for women over the age of 30 to identify women most likely to develop cervical cancer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
- Renault posts revenue beat in Q1, confirms full-year outlook
- Wolfspeed (WOLF) Comments on Letter from JANA Partners
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
